News & Events
QIAGEN has agreed to license exclusive worldwide rights from Insight Genetics Inc. Rights to RET, ROS1 and DEPDC1 biomarkers gained from Insight Genetics offer promise as companion diagnostics in lung cancer
QIAGEN has agreed to license exclusive worldwide rights from Insight Genetics Inc., a molecular diagnostics company in Nashville, Tennessee, for the RET, ROS1 and DEPDC1 biomarkers for use in non-small cell lung cancer (NSCLC), the most common form of lung cancer.
Since 2010, the National Cancer Institute (NCI) has awarded Insight Genetics, Nashville, Tenn, four contracts to develop and refine companion diagnostic tests that identify and characterize specific genetic mutations known to be active in the proliferation of lung and breast cancers. Insight’s tests support physicians in accurately diagnosing and monitoring patients’ cancers to improve personalized treatment.
“We are delighted that NCI continues to recognize our company’s leadership in developing diagnostics that enable the prescription of targeted cancer therapies,” said Insight President and COO Christopher Callaghan.
The contracts are the third and fourth awards the company has received from the National Cancer Institute since 2010.
NEW YORK (GenomeWeb News) – Molecular diagnostics company Insight Genetics said on Monday it has been awarded two SBIR contracts from the National Cancer Institute to develop companion diagnostic tests aimed at lung cancer. The contracts, which total about $1.7 million, will go toward developing tests to identify and characterize specific genetic mutations in lung cancer patients. The tests would help physicians decide which therapies are best suited for individual patients.